# Loop diuretics

Drug · id `cardio:loop-diuretics` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Loop diuretic

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure; Heart failure  

## In plain language

A group of diuretics, medicines that act on the kidney. A US label says one of them inhibits the absorption of sodium and chloride in the kidney tubules, including the loop of Henle. The US label read for one loop diuretic lists swelling from fluid build-up in congestive heart failure, cirrhosis and kidney disease, and says the oral form may also be used for high blood pressure.

## Technical summary

Class page. MeSH descriptor D049994 (Sodium Potassium Chloride Symporter Inhibitors, last updated 2020-05-27) is recorded as a broad match: it is named for the mechanism, and its scope note describes agents that inhibit sodium-potassium-chloride symporters and act as diuretics. MeSH says excess use is associated with low blood potassium and high blood sugar. The label read is the US prescribing label of one brand-name furosemide tablet (application NDA016273, effective 2025-09-30 in openFDA); its openFDA record gives the established pharmacologic class Loop Diuretic. The label covers adults and pediatric patients for edema and adults for hypertension. This page gives no dose, no trial result and no guideline statement, and none of the label's warnings was recorded, including the warning on profound loss of water and electrolytes that opens its warnings section. Medicines of the group that have their own pages are filed under it.

## Claims, with the population each applies to

## Context: Adults and pediatric patients with edema, and adults with hypertension, as described in the US label of a loop diuretic

Recipient: Mixed recipients; Population: Patients described in the indications section of the label: adults and pediatric patients with edema associated with congestive heart failure, cirrhosis of the liver or renal disease, and adults with hypertension.; Care setting: Prescription medicine, as described in the US label; Geography: United States (US drug label); Life stage: Adults and pediatric patients for edema; adults for hypertension, as the label states; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of LASIX (furosemide tablets, Validus Pharmaceuticals LLC, application NDA016273; the version dated 2025-09-30 in openFDA) lists the treatment of edema associated with congestive heart failure, cirrhosis of the liver and renal disease, including the nephrotic syndrome, in adults and pediatric patients. It says oral LASIX may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. openFDA's record gives the established pharmacologic class Loop Diuretic. MeSH says agents of the matching descriptor act as diuretics.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Mixed recipients; Population: Patients described in the indications section of the label: adults and pediatric patients with edema associated with congestive heart failure, cirrhosis of the liver or renal disease, and adults with hypertension.; Care setting: Prescription medicine, as described in the US label; Geography: United States (US drug label); Life stage: Adults and pediatric patients for edema; adults for hypertension, as the label states; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The pharmacologic class name comes from openFDA's record of the label. Other loop diuretic labels list different uses. Contraindications, warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-09
- Sources:
  1. Supports: openFDA drug label record for LASIX (furosemide tablets), Validus Pharmaceuticals LLC label: indications and class description (Regulator, edition The openFDA drug label record for set id 2c9b4d8f-0770-482d-a9e6-9c616a440b1a (manufacturer Validus Pharmaceuticals LLC, application NDA016273), returned on 2026-11-09. The label text is dated 2025-09-30 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%222c9b4d8f-0770-482d-a9e6-9c616a440b1a%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], INDICATIONS AND USAGE. Retrieved 2026-11-09T13:17:37Z. Source state: Current. Version fingerprint: ed9855aad2ab51bda46903f2319af7d32d4fcf9954b059cd6afc33672d16a4f0.
     How it applies: Edema and hypertension uses.
  2. Supports: openFDA drug label record for LASIX (furosemide tablets), Validus Pharmaceuticals LLC label: indications and class description (Regulator, edition The openFDA drug label record for set id 2c9b4d8f-0770-482d-a9e6-9c616a440b1a (manufacturer Validus Pharmaceuticals LLC, application NDA016273), returned on 2026-11-09. The label text is dated 2025-09-30 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%222c9b4d8f-0770-482d-a9e6-9c616a440b1a%22&limit=1>
     Locator: results\[0\].openfda.pharm\_class\_epc\[0\]. Retrieved 2026-11-09T13:17:37Z. Source state: Current. Version fingerprint: ed9855aad2ab51bda46903f2319af7d32d4fcf9954b059cd6afc33672d16a4f0.
     How it applies: Established pharmacologic class in openFDA: Loop Diuretic.
  3. Background: openFDA drug label record for LASIX (furosemide tablets), Validus Pharmaceuticals LLC label: indications and class description (Regulator, edition The openFDA drug label record for set id 2c9b4d8f-0770-482d-a9e6-9c616a440b1a (manufacturer Validus Pharmaceuticals LLC, application NDA016273), returned on 2026-11-09. The label text is dated 2025-09-30 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%222c9b4d8f-0770-482d-a9e6-9c616a440b1a%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:17:37Z. Source state: Current. Version fingerprint: ed9855aad2ab51bda46903f2319af7d32d4fcf9954b059cd6afc33672d16a4f0.
     How it applies: Effective date of the label text read, 20250930.
  4. Supports: MeSH scope note for descriptor D049994 (Sodium Potassium Chloride Symporter Inhibitors) (Dataset, edition MeSH linked-data record of the preferred concept M0471884 of descriptor D049994, fetched 2026-11-09. The scope note is on this concept record, not on the descriptor record.) <https://id.nlm.nih.gov/mesh/M0471884>
     Locator: scopeNote.@value. Retrieved 2026-11-09T13:15:46Z. Source state: Current. Version fingerprint: 5b779b15d6a5e90ccf188a1787b22597dfb8060a2483888d21493018350e5ec7.
     How it applies: MeSH scope note: the agents act as diuretics.

## Connected pages

- A US label lists fluid build-up from congestive heart failure as an indication: Heart failure (`cardio:heart-failure`) [a claim, not a settled fact; see claim `cardio:claim-fda-lasix-label-indications` and its context]
- A US label says the oral form may be used for high blood pressure: Hypertension (high blood pressure) (`core:hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-lasix-label-indications` and its context]
- Blood pressure lowering medicine, the care strategy: Blood pressure lowering medicine (`cardio:bp-lowering-medicine`)
- Files under this front: Medicines (`cardio:front-medicines`)
- Has subtype: Bumetanide (`cardio:bumetanide`)
- Has subtype: Furosemide (`cardio:furosemide`)
- Has subtype: Torsemide (`cardio:torsemide`)

## Provenance

Content hash: 721311ab54f38eb0ea5ad1d622a83fb7f70046fdacf10f6b745fc7aae599c164
Last substantive edit: 2026-11-09
Evidence last checked: 2026-11-09
